Dr Reddy Laboratories : announces the launch of Redyx in India

Press Release

			CONTACT
DR. REDDY'S LABORATORIES LTD.		INVESTOR RELATIONS			MEDIA RELATIONS
8-2-337, Road No. 3, Banjara Hills,		AMIT AGARWAL			APARNA TEKURI
Hyderabad - 500034. Telangana, India.
	[e-mail]			[e-mail]
		(PH: [phone])			(PH: [phone])

Dr. Reddy's Laboratories announces the launch of Redyx in India

Hyderabad, India, September 9, 2020For Immediate Release

…..….…………………………………………………………………………………………………………………………………………………………………...

Hyderabad, India, September 9, 2020 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY,

NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Remdesivir, under a brand name Redyx in India. The launch is part of the licensing agreement with Gilead Sciences, Inc. (Gilead) that grants Dr. Reddy's the right to register, manufacture and sell Remdesivir, a potential treatment for Covid-19, in 127 countries including India.

Remdesivir is approved by Drug Controller General of India (DCGI) for restricted emergency use in India for the treatment of Covid-19 patients hospitalized with severe symptoms.

Dr. Reddy's Redyx is available in strength of 100 mg vial.

M V Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), Dr. Reddy's Laboratories, said "We will continue our efforts to develop products that address significant unmet needs of patients. The launch of Redyx reaffirms our commitment to bringing in critical medicine for patients suffering from Covid-19 in India."

……………………………………………………………………………………..……………………………………………………………………………………………………………………..……………….

About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company,

committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active

Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including APIs, custom

pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal,

cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates in markets across the globe. Our major

markets include - USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

……………………………………………………………………………………………………………………………………………………………………..

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management's current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments,

1. the impact of acquisitions or reorganization, including related integration issues,and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."